In8Bio (INAB) Net Cash Flow (2020 - 2026)

In8Bio has disclosed Net Cash Flow across 7 years of filings, most recently posting -$4.0 million for Q2 2026.

• In Q2 2026, Net Cash Flow fell 400.67% year-over-year to -$4.0 million; the TTM figure through Jun 2026 stood at $4.6 million (up 53.43% YoY), while the FY2025 annual figure was $15.9 million, up 256.88% from the prior year.
• Net Cash Flow came in at -$4.0 million for Q2 2026 at In8Bio, up from -$5.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $16.3 million in Q4 2025 to a low of -$9.5 million in Q4 2022.
• Average Net Cash Flow over 5 years is -$1.1 million, with a median of -$3.4 million recorded in 2024.
• Year-over-year, Net Cash Flow soared 196.37% in 2023 and plunged 768.09% in 2026.
• Over 5 years, Net Cash Flow stood at -$9.5 million in 2022, then surged by 189.06% to $8.4 million in 2023, then decreased by 15.47% to $7.1 million in 2024, then jumped by 129.44% to $16.3 million in 2025, then tumbled by 124.64% to -$4.0 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$4.0 million in Q2 2026, -$5.2 million in Q1 2026, and $16.3 million in Q4 2025.